GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » Beginning Cash Position

K Pharma (TSE:4896) Beginning Cash Position : 円0 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is K Pharma Beginning Cash Position?

K Pharma's Beginning Cash Position for the quarter that ended in Mar. 2024 was 円0 Mil.

K Pharma's annual Beginning Cash Position increased from Dec. 2021 (円17 Mil) to Dec. 2022 (円189 Mil) and increased from Dec. 2022 (円189 Mil) to Dec. 2023 (円1,337 Mil).


K Pharma Beginning Cash Position Historical Data

The historical data trend for K Pharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma Beginning Cash Position Chart

K Pharma Annual Data
Trend Dec21 Dec22 Dec23
Beginning Cash Position
17.15 188.78 1,336.85

K Pharma Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial - - - - -

K Pharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


K Pharma Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of K Pharma's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


K Pharma (TSE:4896) Business Description

Traded in Other Exchanges
N/A
Address
7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032
K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines